drugset / Trial / NCT02472977

Safety and Efficacy Study of Ulocuplumab and Nivolumab in Subjects With Solid Tumors

NCT02472977

Phase 1/2 Terminated 61 enrolled Bristol-Myers Squibb
RandomizedParallel-groupOpen-labelOther

Summary

The purpose of this study is to determine whether the combination of Ulocuplumab and Nivolumab is safe and effective in the treatment of pancreatic cancer and small cell lung cancer.

Timeline

Start
2015-07-13
Primary completion
2017-01-27
Completion
2017-01-27

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nivolumab Monoclonal antibody
Comparator Ulocuplumab Monoclonal antibody

Indications